|
- Ligand Reports First Quarter 2025 Financial Results
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines Ligand does this by providing financing, licensing our technologies or both
- Ligand Pharmaceuticals Incorporated - Investor Relations
Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world
- Ligand Pharmaceuticals Incorporated - Stock Info
All 3m NASDAQ:LGND News Releases Sep 22 Sep 29 Oct 6 Oct 13 Oct 20 Oct 27 Nov 3 Nov 10 Nov 17 Dec 1 Dec 8 Dec 15 2020 2021 2022 2023 2024 2025 140 160 180 200 220 0
- Ligand Pharmaceuticals - Biopharmas Technology and Capital Partner
Ligand invests in the clinical development and commercialization of high-value medicines We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development stage programs
- Ligand Pharmaceuticals Incorporated - Ligand Reports Third Quarter 2025 . . .
For more information, please visit www ligand com Follow Ligand on X and LinkedIn We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD
- Royalty Portfolio - Ligand Pharmaceuticals
Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development-stage programs
- About Us - Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world
- Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Ligand does this by providing financing, licensing our technologies or both Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure
|
|
|